Home » Newsletters » BioWorld Science

BioWorld Science

April 24, 2020

View Archived Issues

Phase IIb study of Rivelin-CLO achieves primary endpoint

Favorable safety seen with MERS-CoV vaccine MVA-MERS-S in phase I study

Cyp2c44 protects against breast tumor growth and metastasis by preventing PGE2 synthesis in mice

ARRB1 shows a tumor-suppressive function in T-ALL by promoting NOTCH1 degradation

AstraZeneca announces initiation of phase III DARE-19 study of Farxiga in COVID-19

First subject dosed in phase I study of TD-0903

RECCE-327 shows significant antibacterial activity against MRSA superbug in vivo

FDA recommends phase III confirmatory study of bucillamine in patients with COVID-19

Algernon receives approval for phase II COVID-19 study of ifenprodil in South Korea

First patient dosed in phase I study of SRF-388

MicroRNA biomarkers in malignant progression of gliomas

Angiotensin-(1-12) as novel biomarker of hypertension and cardiac disease

Annapurna Bio patents apelin receptor agonists

Pfizer discloses new PDE4B inhibitors

FORMA Therapeutics identifies USP30 inhibitors

Nippon Chemical Industrial describes new gold complexes for cancer

PTPN11 inhibitors presented by Gilead Sciences

New approach generates biohybrid microswimmers with nanoerythrosome carriers

Valneva and Dynavax collaborate on vaccine program for COVID-19

NCS1 is a potential therapeutic target for Wolfram syndrome

In antibody ensemble, second fiddles help the neutralizing stars

Phase IIa study of BIO-11006 shows reduced all-cause mortality from ARDS

Phase IIb study of RV-001 in prostate cancer treats first patient in Germany

Summary trial results for CL-2020 in acute myocardial infarction and ischemic stroke

Phase III PROfound trial of Lynparza in CRPC shows statistically significant improvement in OS

Phase I/II study of NOX-A12 in brain cancer cleared to begin second cohort

GARNET data show potential of dostarlimab in recurrent or advanced dMMR endometrial cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...